Top advances of the year: Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34619
Abstract: In the year 2021, there were three new Food and Drug Administration approvals for all leukemia types: asciminib (Scemblix) for chronic myeloid leukemia, brexucabtagene autoleucel (Tecartus) for relapsed/refractory B‐cell acute lymphocytic leukemia, and asparaginase erwinia… read more here.
Keywords: top advances; leukemia; advances year; brexucabtagene autoleucel ... See more keywords
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01797
Abstract: PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial,… read more here.
Keywords: cell; standard care; brexu cel; relapsed refractory ... See more keywords